New drugs for peripheral T-cell lymphomas

Over the past few years, considerable progress has been made in the treatment of patients with non-Hodgkin’s lymphomas (NHL), primarily those with B-cell malignancies. Unfortunately, however, the outcome of patients with peripheral T-cell lymphomas remains disappointing. Although responses can be achieved with intensive combination chemotherapy regimens, relapse is common and few successful salvage therapies are available.